Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.
Launched by FUNDACIÓN CANARIA RAFAEL CLAVIJO PARA LA INVESTIGACIÓN BIOMÉDICA · Feb 25, 2014
Trial Information
Current as of August 24, 2025
Completed
Keywords
ClinConnect Summary
Two key quality indicators for colonoscopy are the cecal intubation rate and the percentage of neoplastic lesions detected. Both factors are associated with adequate bowel cleansing. Poor cleansing ranged from 5% to 30% across studies, negatively affecting the efficiency of colonoscopy.
The most important factor associated with poor colonic preparation is the past history of poor bowel preparation. However, there are no recommendations on the proper type of preparation in those patients. In two non-randomized studies inadequate cleansing in the second colonoscopy ranged from 9.8% to 23%. R...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\> 18 years
- • Outpatients with a history of past poor bowel prep, defined according to the Boston scale as a score less than 5.
- • Signed informed consent
- Exclusion Criteria:
- • paralytic ileus, intestinal obstruction, megacolon, poorly controlled hypertension (systolic pressure\> 180, dyastolic pressure\> 100), congestive heart failure, acute liver failure, end stage renal disease (dialysis or pre-dialysis), New York Heart Association class III-IV, pregnancy, diagnosis of phenylketonuria, diagnosis of glucose-6-phosphate dehydrogenase deficiency, dementia. History of poor preparation in the previous colonoscopy, colon resection, less than 75% intake of the bowel preparation in the index colonoscopy, refusal to participate in the study, patients in whom a new colonoscopy is not indicated despite a poor bowel preparation(i.e. ileal Crohn disease with poor large bowel preparation), lack of compliance with the bowel preparation schedule.
About Fundación Canaria Rafael Clavijo Para La Investigación Biomédica
The Fundación Canaria Rafael Clavijo para la Investigación Biomédica is a dedicated non-profit organization based in the Canary Islands, focused on advancing biomedical research and improving healthcare outcomes. Committed to fostering innovation and collaboration in the scientific community, the foundation supports clinical trials and research initiatives that aim to address pressing health challenges. By facilitating partnerships among researchers, healthcare professionals, and academic institutions, the foundation plays a pivotal role in translating scientific discoveries into practical applications that benefit patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santa Cruz De Tenerife, , Spain
Patients applied
Trial Officials
Antonio Z Gimeno García, MD, PhD
Principal Investigator
Hospital Universitario de Canarias
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials